Portfolio
A diverse pipeline of companies transforming life sciences
Portfolio
A diverse pipeline of companies transforming life sciences
Ansa Biotechnology
An enzymatic DNA synthesis company empowering researchers with rapid, high-accuracy complex DNA constructs to accelerate innovation in biotech and synthetic biology.
Bluejay Therapeutics
A clinical-stage biopharmaceutical company developing novel therapies for chronic viral and liver diseases with significant unmet medical need.
Centaurus
A clinical-stage biotech developing first-in-class therapies targeting ceramide-driven
cardiovascular, kidney, and metabolic diseases.
Hegenomics
A healthcare technology leader in India providing advanced blood and cancer screening solutions to improve early detection and patient safety.
Humboldt
A New York–based venture capital firm investing in early-stage biotech and synthetic biology companies that tackle global challenges and drive transformative technology.
Ilytica
A digital diagnostics company developing AI-powered molecular assays to enable high-sensitivity, decentralized biomarker testing beyond traditional labs.
Invitria
A life sciences company providing animal-free cell culture media and reagents for biologics and cell therapy development.
Kainomyx
A platform biotech leveraging cytoskeletal biology to discover novel small-molecule therapeutics for parasitic, veterinary, agricultural, and human diseases.
Nuclein
A diagnostics company accelerating point-of-care molecular testing with its FDA-cleared DASH Rapid PCR System delivering lab-quality results in minutes.
Omvax
A San Francisco–based biotech developing next-generation meningococcal B vaccines using
native outer membrane vesicles to improve protection across age groups.
PhenoBiome
A precision microbiome therapeutics company engineering targeted bacterial consortia to improve treatment outcomes across human and animal health applications.
Praxis Biotech
A pharmaceutical development company translating synthetic-molecule therapeutics from
research labs into treatments for neurodegenerative diseases.
Pro Lynx
A biotechnology company developing reversible protein-drug conjugate technologies to
precisely control therapeutic activity and improve drug safety.
Pyxis Oncology
A clinical-stage biotech developing next-generation antibody-drug conjugates and
immunotherapies to improve outcomes for patients with difficult-to-treat cancers.
Quince Therapeutics
A clinical-stage biotech advancing precision therapies for severe neurodegenerative and rare
diseases with genetically validated targets.
Soley Therapeutics
A biotech decoding cellular language to design precision therapies that modulate immune
regulation for rare and chronic inflammatory diseases.
Toreador Therapeutics
An oncology biotech developing highly selective T cell engagers using super-resolution microscopy to unlock cancer-specific targeting and improved therapeutic windows.
Trancura Biosciences
A biotechnology company using genomic immune profiling to accelerate de novo monoclonal
antibody discovery for high-value biomedical targets.
Vettore Biosciences
A clinical-stage biotech developing a novel small-molecule MCT4 inhibitor to address pulmonary fibrosis, with potential applications across other fibrotic diseases.